InvestorsHub Logo
Followers 30
Posts 3271
Boards Moderated 0
Alias Born 05/06/2014

Re: None

Monday, 05/16/2016 8:53:44 AM

Monday, May 16, 2016 8:53:44 AM

Post# of 144817
Here are the milestones outlined by KW for 2016 on January 4, 2016. Notice how these things are being completed in order. Almost like they knew what they were doing when outlined this months ago. Oh, they did know what they were doing. That's where the belief comes from. Just watch them check these off and ignore the 2010 cut and paste posts - waste of space. We can add the Diabetes Patent to this list too.

1.) PharmaCyte’s CEO will attend the 2016 JP Morgan Healthcare conference in San Francisco to meet with pharmaceutical companies and potential institutional investors. Complete

2.) The manufacturing facility in Bangkok, Thailand, where the live cells that convert the cancer prodrug ifosfamide into its cancer-killing form will be encapsulated, will receive a factory license from the Thai government enabling production of the encapsulated cells for PharmaCyte to use in its clinical trials. Complete

3.) The Austrianova manufacturing facility will become fully compliant with current Good Manufacturing Practices (cGMP) standards. Complete

NEXT! Coming to PR near you.

4.) An Investigational New Drug Application (IND) will be filed with the FDA following a pre-IND meeting with the FDA.

Numbers 5-9 are other steps for the clinical trial. You can see there are many steps left. This will not happen quickly.

5.) Appropriate arrangements will be made with cancer centers in the United States to begin PharmaCyte’s pancreatic cancer trial that will address the critical unmet medical need that exists when a patient’s non-metastatic, pancreatic cancer no longer benefits from receiving the “gold standard” treatment – the combination of gemcitabine and Abraxane®.

6.)PharmaCyte’s clinical trial in pancreatic cancer will get underway with Translational Drug Development (TD2) coordinating the trial globally and conducting it in the United States. Clinical Network Services (CNS) will conduct the trial in Europe and Australia in alliance with TD2.

7.) After the pancreatic cancer clinical trial has been in process for approximately six months, there will be an evaluation of PharmaCyte’s pancreatic cancer treatment on the patients enrolled in the trial with the interim results being reported to the public.

8.) Additional preclinical studies to determine if PharmaCyte’s pancreatic cancer treatment can slow down the production and accumulation of malignant ascites fluid will take place in 2016. If successful, plans to conduct a clinical trial in ascites will be undertaken by PharmaCyte with the goal of having TD2 begin the clinical trial by year end or early 2017.

9.) Numerous preclinical studies will be conducted concurrently and in parallel by members of PharmaCyte’s international Diabetes Consortium to condense the time it will take for PharmaCyte to enter into a clinical trial that will test the ability of the Melligen insulin-producing cells encapsulated using the Cell-in-a-Box® technology to treat Type 1 diabetes and insulin-dependent Type 2 diabetes, with the goal of reaching the clinic in 2017. Patent step completed toward this.

10.) PharmaCyte will fill its open Board of Directors positions as appropriate. Welcome Dr. Sanjay Bantra and more to follow.

11.) PharmaCyte will conduct periodic shareholder calls, rather than communicating through shareholder updates, with the CEO responding to questions during the calls. Whenever.

12.) PharmaCyte will hold an annual shareholder meeting. Obviously not going to happen until after trials start. They're a little busy right now.

Still a lot of work to do. Don't be in a rush.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PMCB News